RNS Number: 1588D GSK PLC 13 October 2025

GSK plc (the 'Company') Transaction notification

Position/status nitial notification/ amendment Details of the issuer,	Ch	nma Walmsley ief Executive Officer ial notification	
nitial notification/ amendment Details of the issuer,			
emendment Details of the issuer,	Init	ial notification	
auctioneer or auction			rticipant, auction platform,
Name	GS	SK plc	
El	549	93000HZTVUYLO1D793	
ii) each type of trans	sac	tion; (iii) each date; and (iv)	
inancial instrument		,	ch ('Ordinary Shares')
ransaction	div	idends paid to shareholders on	9 October 2025 on shares held
Price(s) and volume(s)			Volume(s)
		£16.3921	29
Aggregated nformation	N//	A (single transaction)	
Aggregated volume Price			
Date of the cransaction	20:	25-10-09	
Place of the transaction	Lo	ndon Stock Exchange (XLON)	
	Details of the transaction each type of transaction of the inancial instrument exaction Aggregated information Aggregated volume Price Date of the ransaction Place of the ransaction	Aggregated nformation Aggregated volume Price Date of the transaction Aggregated volume Price Date of the transaction Aggregated volume Price Date of the ransaction Aggregated volume Price Date of the ransaction	Details of the transaction(s): section to be repeated ii) each type of transaction; (iii) each date; and (iv) ransaction(s) has been conducted Description of the inancial instrument SIN: GB00BN7SWP63 Nature of the ransaction Acquisition of Ordinary Shares foll dividends paid to shareholders on through the Company's Share Rev Price(s) and volume(s) Price(s) Aggregated N/A (single transaction) Aggregated volume Price Date of the ransaction Place of the London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Diana Conrad	
b)	Position/status	Chief People Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
P)	I []	EN03000HZTV/I IVI 04D703	

υj	LEI	D4300001121701L01D	าฮง
3.		saction; (iii) each date	repeated for (i) each type of instrumen e; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 ½ ISIN: GB00BN7SWP63	4 pence each ('Ordinary Shares')
b)	Nature of the transaction	, .	Shares following the re-investment of nolders on 9 October 2025 on shares held Share Reward Plan
c)	Price(s) and volume(s)	Price(s) £16.3921	Volume(s) 5
d)	Aggregated information Aggregated volume	N/A (single transaction)	
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchang	e (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	James Ford		
b)	Position/status	SVP and Group Gen	eral Counsel, Legal and Compliance	
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, auctioneer or auction		e market participant, auction plat	form,
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO	D793	
3.		 saction(s): section to be repeated for (i) each type of instrument insaction; (iii) each date; and (iv) each place where been conducted		
a)	Description of the financial instrument	Ordinary shares of 3	1 1/4 pence each ('Ordinary Shares')	
	maroia morariore	ISIN: GB00BN7SWF	63	
b)	Nature of the transaction	Acquisition of Ordina dividends paid to sha	63 ry Shares following the re-investment reholders on 9 October 2025 on shar r's Share Reward Plan	of res held
b)	Nature of the	Acquisition of Ordina dividends paid to sha through the Compan	ry Shares following the re-investment reholders on 9 October 2025 on shar	of res held
	Nature of the transaction	Acquisition of Ordina dividends paid to sha through the Compan	ry Shares following the re-investment reholders on 9 October 2025 on shar 's Share Reward Plan	of res held
	Nature of the transaction	Acquisition of Ordina dividends paid to sha through the Compan	ry Shares following the re-investment reholders on 9 October 2025 on shar y's Share Reward Plan Volume(s)	e of res held
c)	Nature of the transaction Price(s) and volume(s) Aggregated	Acquisition of Ordina dividends paid to sha through the Company Price(s) £16.3921	ry Shares following the re-investment reholders on 9 October 2025 on shar y's Share Reward Plan Volume(s)	of res held
c)	Nature of the transaction Price(s) and volume(s) Aggregated information Aggregated volume	Acquisition of Ordina dividends paid to sha through the Company Price(s) £16.3921	ry Shares following the re-investment reholders on 9 October 2025 on shar y's Share Reward Plan Volume(s)	of res held

1.	Details of PDMR/per	SOI	n closely associated with the	em ('PCA')
a)	Name	Sa	ally Jackson	
b)	Position/status	S۱	/P, Global Communications a	nd CEO Office
c)	Initial notification/ amendment	lni	tial notification	
2.	Details of the issuer, auctioneer or auction			articipant, auction platform,
a)	Name	G	SK plc	
b)	LEI	54	93000HZTVUYLO1D793	
3.	Details of the transa (ii) each type of tran transaction(s) has be	sa	ction; (iii) each date; and (iv	d for (i) each type of instrument; v) each place where
a)	Description of the financial instrument		dinary shares of 31 $\frac{1}{4}$ pence $\frac{1}{4}$	each ('Ordinary Shares')
b)	Nature of the transaction	di۱		es following the re-investment of on 9 October 2025 on shares held eward Plan
c)	Price(s) and volume(s))	Price(s)	Volume(s)
			£16.3921	19
d)	Aggregated information	N/	A (single transaction)	
	Aggregated volume Price			
e)	Date of the transaction	20	25-10-09	
f)	Place of the transaction	Lo	ndon Stock Exchange (XLON)	

1.	Details of PDMR/pe	erson closely associated with them ('PCA')
a)	Name	Luke Miels
b)	Position/status	Chief Commercial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issue auctioneer or aucti	r, emission allowance market participant, auction platform, on monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.		action(s): section to be repeated for (i) each type of instrument; nsaction; (iii) each date; and (iv) each place where been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
h)	Nature of the	Acquisition of Ordinary Shares following the re-investment of

~,	transaction	dividends paid to shal through the Company's	reholders on 9 October 2025 on sh	nares held
c)	Price(s) and volume(s)	Price(s)	Volume(s)	
		£16.3921	3	
d)	Aggregated information	N/A (single transactior	n)	
	Aggregated volume Price			
e)	Date of the transaction	2025-10-09		
f)	Place of the transaction	London Stock Exchan	ge (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	David Redfern	
b)	Position/status	President Corporate Development	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auction	emission allowance market participant, auction platform, n monitor	
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.		ction(s): section to be repeated for (i) each type of instrument; saction; (iii) each date; and (iv) each place where en conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63	
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025 on shares held through the Company's Share Reward Plan	
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.3921 76	
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')	
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain

c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auction		narket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D7	93
3.		saction; (iii) each date	epeated for (i) each type of instrument; ; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 1/4	pence each ('Ordinary Shares')
b)	Nature of the transaction		Shares following the re-investment of olders on 9 October 2025 on shares held Share Reward Plan
c)	Price(s) and volume(s)) Price(s)	Volume(s)
		£16.3921	29
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-10-09	
•	transaction		

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Philip Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issue auctioneer or aucti		ket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.		nsaction; (iii) each date; ar	eated for (i) each type of instrument ad (iv) each place where
3.	(ii) each type of tra	nsaction; (iii) each date; ar been conducted	
	(ii) each type of tra transaction(s) has be Description of the	nsaction; (iii) each date; ar been conducted Ordinary shares of 31 ¼ pe ISIN: GB00BN7SWP63 Acquisition of Ordinary Sha	nd (iv) each place where nce each ('Ordinary Shares') res following the re-investment of each on 9 October 2025 on shares held
a)	(ii) each type of tra transaction(s) has be Description of the financial instrument	ordinary shares of 31 1/4 pe ISIN: GB00BN7SWP63 Acquisition of Ordinary Shadividends paid to sharehold through the Company's Sha	nd (iv) each place where nce each ('Ordinary Shares') res following the re-investment of each on 9 October 2025 on shares held
a) b)	(ii) each type of tra transaction(s) has be Description of the financial instrument Nature of the transaction	ordinary shares of 31 1/4 pe ISIN: GB00BN7SWP63 Acquisition of Ordinary Shadividends paid to sharehold through the Company's Sha	res following the re-investment of ers on 9 October 2025 on shares held are Reward Plan

	Aggregated volume Price	
e)	Date of the transaction	2025-10-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Deborah Waterhouse	
b)	Position/status	CEO, ViiV Healthcare ar	nd President, Global Health, GSK
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auction		arket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D7	93
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')
b)	Nature of the transaction		r Shares following the re-investment of holders on 9 October 2025 on shares held Share Reward Plan
c)	Price(s) and volume(s)	Price(s) £16.3921	Volume(s)
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange	(XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Victoria Whyte	
b)	Position/status	SVP & Company Secretary	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	

3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument		dinary shares of 31 ¼ pence eans. N: GB00BN7SWP63	nch ('Ordinary Shares')
b)	Nature of the transaction	di۱	equisition of Ordinary Shares fol idends paid to shareholders on rough the Company's Share Rev	9 October 2025 on shares held
c)	Price(s) and volume(s))	Price(s) £16.3921	Volume(s) 58
d)	Aggregated information Aggregated volume Price	N/	A (single transaction)	
e)	Date of the transaction	20	25-10-09	
f)	Place of the transaction	Lo	ndon Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Sally Jackson	
b)	Position/status	SVP, Global Commu	nications and CEO Office
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1	D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31	1/4 pence each ('Ordinary Shares') 63
b)	Nature of the transaction		y Shares following the re-investment of reholders on 9 October 2025.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£16.4016	1
d)	Aggregated	N/A (single transaction	on)
	information Aggregated volume		
	Aggregated volume Price	2005 40 00	
e)	Aggregated volume	2025-10-09	

a)	Name	Victoria Whyte			
b)	Position/status	SVP & Company Secr	etary		
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, auctioneer or auction		emission allowance market participant, auction platform, n monitor		
a)	Name	GSK plc			
b)	LEI	5493000HZTVUYLO1D793			
3.	(ii) each type of tran	etails of the transaction(s): section to be repeated for (i) each type of instrument;) each type of transaction; (iii) each date; and (iv) each place where ansaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63			
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.			
c)	Price(s) and volume(s) Price(s)	Volume(s)		
		£16.4016	123		
d)	Aggregated information	N/A (single transaction)		
	Aggregated volume				
	Price				
e)	Date of the transaction	2025-10-09			

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	lai	n Whyte	
b)	Position/status	PC	CA of Ms V Whyte (SVP & Co	ompany Secretary)
c)	Initial notification/ amendment	Ini	tial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	GS	SK plc	
b)	LEI	54	93000HZTVUYLO1D793	
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument		dinary shares of 31 ¼ pence on the shares of 31 ¼ pence on the shares of 31 ½ pence of	each ('Ordinary Shares')
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.		
c)	Price(s) and volume(s))	Price(s) £16.4016	Volume(s) 1,152
		1		

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	
e)	Date of the transaction	2025-10-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		market participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1E	0793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the financial instrument	Ordinary shares of 31 ISIN: GB00BN7SWP6	1/4 pence each ('Ordinary Shares') 3
b)	Nature of the transaction		Shares following the re-investment of eholders on 9 October 2025.
c)	Price(s) and volume(s	Price(s)	Volume(s)
		£16.4016	105.836
d)	Aggregated information	N/A (single transaction	1)
	Aggregated volume Price		
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchan	ge (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Diana Conrad	
b)	Position/status	Chief People Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
- 1		look at	

a)	Name	GSK pic	
b)	LEI	5493000HZTVUYLO1D	793
3.		saction; (iii) each dat	repeated for (i) each type of instrument; e; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 1 ISIN: GB00BN7SWP6	¼ pence each ('Ordinary Shares') 3
b)	Nature of the transaction		Shares following the re-investment of sholders on 9 October 2025.
c)	Price(s) and volume(s)	Price(s) £16.4016	Volume(s) 1,233.149
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price		
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchan	ge (XLON)

	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	James Ford	
b)	Position/status	SVP and Group General (Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auction		arket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D79	3
3.	Details of the transaction(s): section to be repeated for (i) each type of instrumen (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted		
a)	Description of the		pence each ('Ordinary Shares')
•	financial instrument	ISIN: GB00BN7SWP63	,
b)	Nature of the transaction		nares following the re-investment of
b)	Nature of the	Acquisition of Ordinary Sh dividends paid to sharehol	nares following the re-investment of
	Nature of the transaction	Acquisition of Ordinary Sh dividends paid to sharehol	nares following the re-investment of Iders on 9 October 2025.
c)	Nature of the transaction	Acquisition of Ordinary Sh dividends paid to sharehol Price(s)	nares following the re-investment of lders on 9 October 2025. Volume(s)
	Nature of the transaction Price(s) and volume(s) Aggregated	Acquisition of Ordinary Sh dividends paid to sharehol Price(s) £16.4016	nares following the re-investment of lders on 9 October 2025. Volume(s)

,	transaction	
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')			m ('PCA')		
a)	Name	Sa	ally Jackson			
b)	Position/status	S	VP, Global Communications an	d CEO Office		
c)	Initial notification/ amendment	lni	itial notification			
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	G	SK plc			
b)	LEI	54	193000HZTVUYLO1D793			
3.		sa	ction; (iii) each date; and (iv)	for (i) each type of instrument; each place where		
a)	Description of the financial instrument		rdinary shares of 31 ¼ pence eauly: GB00BN7SWP63	ach ('Ordinary Shares')		
b)	Nature of the transaction		cquisition of Ordinary Shares fo vidends paid to shareholders on			
c)	Price(s) and volume(s)		Price(s)	Volume(s)		
			£16.4016	453.008		
d)	Aggregated information	N	'A (single transaction)			
	Aggregated volume Price					
e)	Date of the transaction	20	025-10-09			
f)	Place of the transaction	Lo	ondon Stock Exchange (XLON)			

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Dylan Jackson		
b)	Position/status	PCA of Sally Jackson (SVP, Global Communications and CEO Office)		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
3.		saction(s): section to be repeated for (i) each type of instrument; ansaction; (iii) each date; and (iv) each place where		

I	น ฉาเอฉบนบาเเอ) าเฉอ มธ	CI	CONTINUOLEU	ĺ
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63		
b)			quisition of Ordinary Shares fol idends paid to shareholders on	
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.4016	140.210
d)	Aggregated information	N/.	A (single transaction)	
	Aggregated volume Price			
e)	Date of the transaction	20	25-10-09	
f)	Place of the transaction	Lo	ndon Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')						
a)	Name	David Redfern					
b)	Position/status	President Corporate De	evelopment				
c)	Initial notification/ amendment	Initial notification					
2.		tails of the issuer, emission allowance market participant, auction platform, ctioneer or auction monitor					
a)	Name	GSK plc					
b)	LEI	5493000HZTVUYLO1D	793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted						
a)	Description of the financial instrument	Ordinary shares of 31 1/4 pence each ('Ordinary Shares') ISIN: GB00BN7SWP63					
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 9 October 2025.					
c)	Price(s) and volume(s) Price(s)	Volume(s)				
		£16.4016	6,278.135				
d)	Aggregated information	N/A (single transaction					
	Aggregated volume Price						
e)	Date of the transaction	2025-10-09					
f)	Place of the transaction	London Stock Exchang	je (XLON)				

1.	Details of PDMR/per	ils of PDMR/person closely associated with them ('PCA')					
a)	Name	Re	egis Simard				
b)	Position/status	Pr	esident, Global Suppl	y Chain			
c)	Initial notification/ amendment	lni	tial notification				
2.		ils of the issuer, emission allowance market participant, auction platform, oneer or auction monitor					
a)	Name	GS	SK plc				
b)	LEI	54	93000HZTVUYLO1D7	93			
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted						
a)	Description of the financial instrument		dinary shares of 31 ½ N: GB00BN7SWP63	pence each ('Ordinary Shares')			
b)	Nature of the transaction			Shares following the re-investment of olders on 9 October 2025.			
c)	Price(s) and volume(s))	Price(s)	Volume(s)			
			£16.4016	2,616.351			
d)	Aggregated information	N/	A (single transaction)				
	Aggregated volume Price						
e)	Date of the transaction	20	25-10-09				
f)	Place of the transaction	Lo	ndon Stock Exchange	e (XLON)			

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Philip Thomson				
b)	Position/status	President, Global Affairs				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				

b)	Nature of the transaction	Acquisition of Ordinary Shares following the dividends paid to shareholders on 9 October	
c)	Price(s) and volume(s)	Price(s) Volume(s £16.4016 2,144.723	,
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-10-09	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	K	ate Thomson			
b)	Position/status	P	CA of Philip Thomson	(President	r, Global Affairs)	
c)	Initial notification/ amendment	ln	itial notification			
2.	Details of the issue auctioneer or auct			market pa	rticipant, auction platform,	
a)	Name	G	SK plc			
b)	LEI	54	493000HZTVUYLO1D	793		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument		rdinary shares of 31 ½ SIN: GB00BN7SWP63		ch ('Ordinary Shares')	
b)	Nature of the transaction		cquisition of Ordinary vidends paid to share		owing the re-investment of 9 October 2025.	
c)	Price(s) and volume	(s)	Price(s)		Volume(s)	
			£16.4016		109.382	
		N.	/A (single transaction)		
d)	Aggregated information			,		
d)				,		
d) e)	information Aggregated volume		025-10-09			

1.	Details of PDMR/p	erson closely associated with them ('PCA')
a)	Name	Dehorah Waterhouse

aj	INGILIG	Debolaii vvateiilouse					
b)	Position/status	CEO, ViiV Healthcare ar	nd President, Global Health, GSK				
c)	Initial notification/ amendment	Initial notification					
2.		Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc					
b)	LEI	5493000HZTVUYLO1D7	93				
3.		saction; (iii) each date;	repeated for (i) each type of instrument; ; and (iv) each place where				
a)	Description of the financial instrument	Ordinary shares of 31 1/4	pence each ('Ordinary Shares')				
	manciai metrament	ISIN. GBOODIN/SVVF03					
b)		Acquisition of Ordinary S	Shares following the re-investment of olders on 9 October 2025.				
b)	Nature of the	Acquisition of Ordinary S dividends paid to shareh					
	Nature of the transaction	Acquisition of Ordinary S dividends paid to shareh	olders on 9 October 2025.				
	Nature of the transaction Price(s) and volume(s)	Acquisition of Ordinary S dividends paid to shareh Price(s)	Volume(s) 1,279.528				
c)	Nature of the transaction Price(s) and volume(s) Aggregated	Acquisition of Ordinary S dividends paid to shareh Price(s) £16.4016	Volume(s) 1,279.528				
c)	Nature of the transaction Price(s) and volume(s) Aggregated information Aggregated volume	Acquisition of Ordinary S dividends paid to shareh Price(s) £16.4016	Volume(s) 1,279.528				

1.	Details of PDMR/person closely associated with them ('PCA')			
a)	Name	Tony Wood		
b)	Position/status	Chief Scientific Officer		
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer, auctioneer or auctio	emission allowance market pn monitor	participant, auction platform,	
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1D793		
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted			
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence e ISIN: GB00BN7SWP63	each ('Ordinary Shares')	
b)	Nature of the transaction	Acquisition of Ordinary Shares for dividends paid to shareholders o		
c)	Price(s) and volume(s)	Price(s)	Volume(s)	

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	
e)	Date of the transaction	2025-10-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/pers	DMR/person closely associated with them ('PCA')				
a)	Name	Victoria Whyte				
b)	Position/status	S	VP & Company Secretary			
c)	Initial notification/ amendment	lni	itial notification			
2.	Details of the issuer, auctioneer or auction		mission allowance market pa monitor	rticipant, auction platform,		
a)	Name	GSK plc				
b)	LEI	54	193000HZTVUYLO1D793			
3.	Details of the transaction (ii) each type of transaction(s) has be	sa	ction; (iii) each date; and (iv)	for (i) each type of instrument; each place where		
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63				
b)	Nature of the transaction		equisition of Ordinary Shares fol widends paid to shareholders on			
c)	Price(s) and volume(s)		Price(s)	Volume(s)		
			£16.4016	1.332		
d)	Aggregated information	N	A (single transaction)			
	Aggregated volume Price					
e)	Date of the transaction	20	025-10-09			
f)	Place of the transaction	Lc	ondon Stock Exchange (XLON)			

1.	Details of PDMR/p	erson closely associated with them ('PCA')
a)	Name	Elizabeth McKee Anderson
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issue auctioneer or auct	er, emission allowance market participant, auction platform, tion monitor

a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.		ction(s): section to be repeated for (i) each type of instrument; esaction; (iii) each date; and (iv) each place where een conducted				
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W2044				
b)	Nature of the transaction	Acquisition of ADSs following the re-investment of dividends paid to shareholders on 9 October 2025				
c)	Price(s) and volume(s)	Price(s)	Volume(s)			
		43.7375	26			
d)	Aggregated information	N/A (single transac	etion)			
	Aggregated volume Price					
e)	Date of the transaction	2025-10-10				
f)	Place of the transaction	New York Stock E	xchange (XNYS)			

1.	Details of PDMR/person closely associated with them ('PCA')						
a)	Name	Charles Bancroft					
b)	Position/status	Senior Independent Non	-Executive Director				
c)	Initial notification/ amendment	Initial notification					
2.	Details of the issuer, auctioneer or auction	emission allowance n n monitor	narket participant, auction platform,				
a)	Name	GSK plc					
b)	LEI	5493000HZTVUYLO1D793					
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted						
a)	Description of the financial instrument	American Depositary Sh ISIN: US37733W2044	nares ('ADSs')				
b)	Nature of the transaction	Acquisition of ADSs follo shareholders on 9 Octob	owing the re-investment of dividends paid to per 2025				
c)	Price(s) and volume(s)	Price(s)	Volume(s)				
		43.7375	340				
d)	Aggregated information	N/A (single transaction)					
	Aggregated volume Price						
e)	Date of the transaction	2025-10-10					

I			
	f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/per	rson closely associated with them ('PCA')				
a)	Name	Dr Hal Barron				
b)	Position/status	Non-Executive Director				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, auctioneer or auction			participant, auction platform,		
a)	Name	GSK plc				
b)	LEI	54	493000HZTVUYLO1D793			
3.	(ii) each type of tran	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted				
a)	Description of the financial instrument		merican Depositary Shares ('A IIN: US37733W2044	ADSs')		
b)	Nature of the transaction		cquisition of ADSs following th nareholders on 9 October 2025	ne re-investment of dividends paid to		
c)	Price(s) and volume(s))	Price(s)	Volume(s)		
			43.7375	28		
d)	Aggregated information	N	/A (single transaction)			
	Aggregated volume Price					
e)	Date of the transaction	20	025-10-10			
f)	Place of the transaction	N	ew York Stock Exchange (XN	YS)		

1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Dr Anne Beal				
b)	Position/status	Independent Non-Executive Director				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D793				
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted					
a)	Description of the financial instrument	American Depositary Shares ('ADSs')				

		IOI	IN. USSI I SSVVZU TTI	
b)			equisition of ADSs following the areholders on 9 October 2025	e re-investment of dividends paid to
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			43.7375	34
d)	Aggregated information	N/.	A (single transaction)	
	Aggregated volume Price			
e)	Date of the transaction	20	25-10-10	
f)	Place of the transaction	Nε	w York Stock Exchange (XNY	(S)

1.	Details of PDMR/per	PDMR/person closely associated with them ('PCA')			n ('PCA')
a)	Name	Dr	Harry Dietz		
b)	Position/status	Independent Non-Executive Director			
c)	Initial notification/ amendment	Initial notification			
2.	Details of the issuer, auctioneer or auction			narket pai	ticipant, auction platform,
a)	Name	GSK plc			
b)	LEI	5493000HZTVUYLO1D793			
3.	Details of the transa (ii) each type of tran transaction(s) has be	nsac	ction; (iii) each date;		or (i) each type of instrument; each place where
	uarisaction(s) nas be	een	Conducted		
a)	Description of the financial instrument	An	nerican Depositary Sh N: US37733W2044	ares ('ADS	Ss')
a) b)	Description of the	An ISI	nerican Depositary Sh N: US37733W2044	owing the r	Ss') re-investment of dividends paid to
,	Description of the financial instrument Nature of the	An ISI Ac sha	nerican Depositary Sh N: US37733W2044 quisition of ADSs follo	owing the r per 2025	
b)	Description of the financial instrument Nature of the transaction	An ISI Ac sha	nerican Depositary Sh N: US37733W2044 equisition of ADSs follo areholders on 9 Octob	owing the r per 2025	e-investment of dividends paid to
b)	Description of the financial instrument Nature of the transaction	An ISI Ac sha	nerican Depositary Sh N: US37733W2044 equisition of ADSs follo areholders on 9 Octob Price(s)	owing the r per 2025	e-investment of dividends paid to
b)	Description of the financial instrument Nature of the transaction Price(s) and volume(s) Aggregated	An ISI Ac sha	nerican Depositary Sh N: US37733W2044 equisition of ADSs folloareholders on 9 Octob Price(s)	owing the r per 2025	e-investment of dividends paid to
b)	Description of the financial instrument Nature of the transaction Price(s) and volume(s) Aggregated information Aggregated volume	Am ISII	nerican Depositary Sh N: US37733W2044 equisition of ADSs folloareholders on 9 Octob Price(s)	owing the r per 2025	e-investment of dividends paid to

1.	Details of PDMR/per	son closely associated with them ('PCA')
- \	A1	b. c

a)	Name	Dr Jeannie Lee				
b)	Position/status	Independent Non-Executive Director				
c)	Initial notification/ amendment	Initial notification				
2.	Details of the issuer, auctioneer or auctio		arket participant, auction platform,			
a)	Name	GSK plc				
b)	LEI	5493000HZTVUYLO1D79	93			
3.	Details of the transaction (ii) each type of transaction(s) has be	saction; (iii) each date;	epeated for (i) each type of instrument; and (iv) each place where			
a)	Description of the financial instrument	American Depositary Sh ISIN: US37733W2044	ares ('ADSs')			
b)	Nature of the transaction	Acquisition of ADSs follo shareholders on 9 Octob	wing the re-investment of dividends paid to er 2025			
c)	Price(s) and volume(s)	` '	Volume(s)			
		43.7375	13			
d)	Aggregated information	N/A (single transaction)				
	Aggregated volume Price					
e)	Date of the transaction	2025-10-10				
	Place of the	New York Stock Exchan	0.4.7.45			

	lialisaction					
f)	Place of the transaction	Ne	ew York Stock Exchange (XNY)	S)		
1.	Details of PDMR/per	SOI	n closely associated with the	m ('PCA')		
a)	Name	Dr	· Vishal Sikka			
b)	Position/status	Ind	dependent Non-Executive Direc	tor		
c)	Initial notification/ amendment	Ini	tial notification			
2.	Details of the issuer, auctioneer or auction		mission allowance market pa monitor	articipant, auction platform,		
a)	Name	G	SK plc			
b)	LEI	54	93000HZTVUYLO1D793			
3.	Details of the transa (ii) each type of tran transaction(s) has be	for (i) each type of instrument; each place where				
a)	Description of the financial instrument		American Depositary Shares ('ADSs') ISIN: US37733W2044			
b)	Nature of the transaction		equisition of ADSs following the pareholders on 9 October 2025	re-investment of dividends paid to		
c)	Price(s) and volume(s)	Price(s)	Volume(s)		
		1	43.7375	99		

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	
e)	Date of the transaction	2025-10-10
f)	Place of the transaction	New York Stock Exchange (XNYS)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact msc.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFFWFLDEISEFS